NGL Fine-Chem Limited (BOM:524774)

Market Cap	13.84B +31.0%
Revenue (ttm)	4.49B +9.9%
Net Income	353.73M -49.3%
EPS	57.25 -49.5%
Shares Out	6.18M
PE Ratio	39.13
Forward PE	n/a
Dividend	1.75 (0.08%)
Ex-Dividend Date	Aug 12, 2025

Volume	301
Average Volume	965
Open	2,241.50
Previous Close	2,242.65
Day's Range	2,221.00 - 2,318.90
52-Week Range	962.70 - 2,596.00
Beta	0.38
RSI	76.47
Earnings Date	Feb 3, 2026

About NGL Fine-Chem

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltra...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1981
• Employees: 520
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524774

Financial Performance

In fiscal year 2025, NGL Fine-Chem's revenue was 3.68 billion, an increase of 8.73% compared to the previous year's 3.39 billion. Earnings were 211.24 million, a decrease of -48.87%.